Comparative insights into upper tract urothelial carcinoma: Aligning Chinese Urological Association and European Association of Urology guidelines with clinical practice Authors: Shuxiong Zeng, Wei He, Zhensheng Zhang Published: 2026 Introduction Upper tract urothelial carcinoma (UTUC), arising in the renal pelvis and ureter, represents an uncommon yet clinically formidable subset of urothelial malignancies. Its management is inherently complicated by anatomical constraints, challenges in achieving accurate preoperative staging, and generally worse oncological outcomes compared with those of bladder cancer. Recent guideline updates from the European Association of Urology (EAU) and the Chinese Urological Association (CUA) share the foundational goals of oncologic control and renal preservation, yet they diverge in several specific recommendations [1,2]. This editorial compares the CUA and EAU frameworks, highlighting key areas of consensus and notable differences. Furthermore, it contextualizes recent diagnostic and therapeutic advances, with particular emphasis on how emerging trial data are reshaping UTUC management and how these developments align with current guideline trajectories. Convergence in foundational framework: Risk-stratified management pathways Both the EAU and CUA endorse a pragmatic, risk-adapted, stepwise approach to UTUC, tightly linking diagnostic certainty to the intensity of subsequent local and systemic therapies. The diagnostic pathway in both guidelines is anchored by computed tomography urography and cystoscopy, which are essential for evaluating the upper tracts and excluding synchronous bladder tumors. While urinary cytology is highly specific for high-grade disease, its limited sensitivity precludes its use in isolation. Consequently, when imaging or cytology yields inconclusive results—or when kidney-sparing surgery is contemplated—diagnostic ureteroscopy with targeted biopsy, supplemented by selective upper-tract cytology, is strongly recommended to accurately map tumor grade and distribution [3]. Treatment decisions fundamentally hinge on histologic grade as a primary prognostic surrogate, following a strict low- versus high-risk paradigm. Patients meeting low-risk criteria (unifocal lesion <2 cm, low histologic grade, and no radiologic evidence of invasion) are generally steered toward kidney-sparing modalities, such as endoscopic ablation or segmental ureterectomy. These approaches mandate rigorous postoperative surveillance and routine second-look ureteroscopy. Conversely, patients harboring high-risk features (tumor ≥2 cm, hydronephrosis, high-grade cytology or biopsy, multifocality, or invasive imaging characteristics) are typically managed with radical nephroureterectomy and bladder-cuff excision. The choice among open, laparoscopic, or robotic approaches is individualized based on surgeon expertise and patient factors [4]. Postoperatively, both guidelines advocate for a single, immediate intravesical chemotherapy instillation to mitigate bladder recurrence. They also uniformly acknowledge the survival benefit of adjuvant platinum-based chemotherapy following radical nephroureterectomy, as established by the POUT trial, though both frameworks issue cautions regarding the decline in postoperative renal function, which can severely limit the feasibility of subsequent systemic therapies [5]. Divergences in nuances and specific recommendations Despite their shared foundational principles, the CUA and EAU guidelines differ across several critical domains, reflecting distinct regional realities. Epidemiologically, the CUA explicitly highlights that UTUC accounts for a substantially higher proportion of all urothelial tumors in China than in Western countries (approximately 9.3%–29.9% versus 5%–10%) [2]. This wide prevalence range within Chinese cohorts is multifactorial, stemming from striking geographic disparities in localized environmental exposures—most notably regional variations in the use of aristolochic acid-containing herbal medicines and arsenic exposure—as well as institutional referral biases across different tiers of treating centers. Consequently, the CUA guidelines provide highly detailed operational workflows for Lynch syndrome screening and familial genetic counseling to address these unique public health imperatives [6]. In the realm of imaging and staging, the EAU conditionally recommends 18F-fluorodeoxyglucose positron emission tomography (PET)/CT for selected high-risk patients to enhance the detection of nodal and distant metastases, drawing on retrospective multicenter data that show nodal sensitivity and specificity of roughly 82% and 84%, respectively. In contrast, the CUA does not prioritize PET/CT as a routine diagnostic element, indicating a more conservative assessment of evidence maturity and regional resource allocation [7]. Similarly, surgical recommendations for lymph node dissection (LND) vary. The EAU issues a weak recommendation for template-based LND in high-risk, non-metastatic cases, citing improved staging accuracy and potential gains in cancer-specific survival. The CUA adopts a more cautious stance, advising that decisions regarding LND be highly individualized, weighing tumor invasiveness against surgeon experience and institutional capabilities [8,9]. Systemic therapy recommendations also contrast prominently, driven largely by the timing of guideline publications relative to pivotal trial readouts and regulatory approvals. The 2025 EAU update, heavily informed by the EV-302 trial [10,11], incorporates enfortumab vedotin (EV) plus pembrolizumab as a first-line standard for eligible metastatic patients and strongly recommends next-generation sequencing-based fibroblast growth factor receptor 2/3 fusion testing [[12], [13], [14]]. The CUA guidelines, published prior to these paradigm-shifting approvals, maintain platinum-based combination chemotherapy as the first-line standard, integrating immune checkpoint inhibitors and antibody-drug conjugates (ADCs) more conservatively [2]. However, it is noteworthy that subsequent Chinese national updates (e.g., the Chinese Society of Clinical Oncology guidelines) are rapidly adopting EV plus pembrolizumab as evidence accumulates and domestic drug access evolves [15]. Finally, regarding molecular diagnostics, the CUA proactively endorses emerging non-invasive urine assays—such as methylation tests and urine-sediment genomics—as optional diagnostic adjuncts, whereas the EAU places its primary molecular focus on next-generation sequencing-based fibroblast growth factor receptor 2/3 fusion testing in the metastatic setting. Integration of recent advances and future directions Recent years have witnessed transformative advances in the management of advanced urothelial carcinoma. However, when evaluating these rapid developments, it is still vital to maintain a clear distinction between UTUC-specific evidence and data extrapolated from bladder cancer cohorts. Lessons from bladder cancer extrapolation In the perioperative setting, landmark trials predominantly involving muscle-invasive bladder cancer have set new therapeutic benchmarks. For instance, trials such as VESPER and NIAGARA have established the superiority of intensified neoadjuvant chemotherapy and the perioperative integration of immune checkpoint inhibitors [16,17]. In the adjuvant space, IMvigor011 introduced circulating tumor DNA as a predictive tool to guide risk-adapted postoperative immune checkpoint inhibitor therapy [18]. Moreover, the remarkable metastatic efficacy of ADCs—such as EV plus pembrolizumab or disitamab vedotin plus toripalimab—has prompted ongoing phase III trials (e.g., EV-304) to evaluate their perioperative utility [10,19]. Together with refined bladder-preserving protocols [20], these bladder cancer-derived breakthroughs provide a compelling, albeit extrapolated, strategic framework for UTUC management. The rise of UTUC-specific evidence Crucially, the field is now rapidly generating UTUC-specific high-level evidence to validate these adapted strategies. Building upon the established adjuvant chemotherapy benefits from the POUT trial [21], emerging data support robust neoadjuvant approaches. Recent reports on neoadjuvant chemotherapy for high-risk UTUC describe impressive long-term survival outcomes [22,23]. Meanwhile, neoadjuvant chemoimmunotherapy is showing significant promise for disease downstaging; trials such as iNDUCT-GETUG V08 and WUTSUP-01 have demonstrated substantial pathological complete response rates and encouraging early survival profiles in locally advanced disease [24,25]. Innovations in diagnostics and organ preservation Simultaneously, innovations in diagnostics and targeted therapies are pioneering new frontiers in organ preservation. For example, UroCAD—a novel urine-based assay utilizing chromosomal copy number variation analysis—has demonstrated high diagnostic accuracy for non-invasive UTUC detection and molecular stratification [26]. When coupled with novel therapeutic regimens—such as the DISTINCT-I trial’s paradigm combining the HER2-targeted ADC disitamab vedotin with tislelizumab—these tools facilitate high clinical response rates that may eventually allow high-risk patients to safely undergo kidney-preserving treatment strategies [27]. Collectively, these advances highlight a dual evolution in UTUC care: the intensification of systemic therapy for superior oncological control, and the refinement of personalized, non-invasive early diagnostics to enable organ-preserving strategies. Conclusion The divergent recommendations between the CUA and EAU guidelines are not merely the result of academic disagreements, but rather a reflection of a complex interplay of real-world determinants. Regulatory and economic contexts—particularly disparities in drug approval timelines and reimbursement policies—directly dictate the accessibility of novel therapeutics and the pace of their integration into clinical guidelines. Distinct regional biological profiles, such as the etiologic impact of aristolochic acid and variations in genetic screening infrastructures, necessitate localized priorities in risk stratification. Furthermore, resource availability, encompassing advanced imaging, molecular diagnostics, and specialized surgical expertise, largely determines the feasibility of interventions such as PET/CT or template-based lymphadenectomy. The historical reliance on evidence extrapolated from bladder cancer cohorts underscores the ongoing need to carefully balance external data against local clinical realities. Against this backdrop, UTUC management is unequivocally advancing toward a more integrated, precise, and personalized paradigm. Non-invasive molecular tools such as UroCAD and circulating tumor DNA analysis promise to revolutionize early detection and dynamic risk stratification. Alongside this, potent neoadjuvant regimens, particularly chemoimmunotherapy and ADC-based combinations, are not only reshaping advanced disease management but also expanding the horizons for kidney-sparing surgery. Future progress will depend on the rigorous validation of predictive biomarkers and the definition of optimal therapeutic sequencing within UTUC-specific perioperative trials. Ultimately, the convergence of precise diagnostics, biologically rational systemic treatments, and response-adapted local therapies will shape the next generation of UTUC care, forging a holistic framework that maximizes oncological outcomes while preserving renal function and patient quality of life. Author contributions Study concept and design: Shuxiong Zeng, Wei He, Zhensheng Zhang. Drafting of the manuscript: Shuxiong Zeng, Wei He, Zhensheng Zhang. Critical revision of the manuscript: Shuxiong Zeng, Wei He, Zhensheng Zhang. Supervision: Shuxiong Zeng, Zhensheng Zhang. Conflicts of interest The authors declare no conflict of interest. Acknowledgements This research was supported by the Yuanhang Talent Program of Naval Medical University (No. 2025011733 to Zeng S). References